Category - Feature

Feature

IntelGenx to regain WW rights to commercialize Rizaport

By Len Zehrs Early in January, IntelGenx (OTCQX:IGXT; TSXV:IGX) will regain exclusive worldwide rights to develop and commercialize its Rizaport oral thin-film treatment of acute migraines. The move follows a decision...

December 19, 2017

Feature

Soricimed planning to initiate Phase 1b/2a solid tumor trial in Q2

By Len Zehrs Closely-held Soricimed Biopharma expects to initiate in the second quarter of 2018 a Phase 1b/2a clinical trial with its SOR-C13 drug candidate in patients with prostate cancer, including men who have...

December 12, 2017

Feature

Crescita targeting $50-million in revenue in 5 years

By Len Zehrs Crescita Therapeutics (TSX:CTX), is aiming to be a $50-million commercial dermatology company in the next five years, with a portfolio of non-prescription skincare products and prescription drug products...

December 5, 2017

Feature

BioLight dry eye subsidiary approaching CE Mark filing, U.S. pivotal trial

By Len Zehrs DiagnosTear, the dry eye diagnostic subsidiary of BioLight Life Sciences (TASE:BOLT), hopes to file by the end of 2017 for CE Mark approval in Europe and begin a pivotal trial in the U.S. in mid-2018 with...

November 28, 2017

Feature

GeNeuro pioneering HERVs against neurodegenerative and autoimmune diseases

By Len Zehrs Swiss-based GeNeuro (Euronext Paris: CH0308403085 – GNRO) is leveraging the biology of human endogenous retroviruses (HERVs) to stop the causes of neurodegenerative and autoimmune diseases, such as multiple...

November 21, 2017

Feature

Marrone Bio focused on 2 near-term pest management products

By Len Zehrs Marrone Bio Innovations (NASDAQ:MBII), which recently received EPA approval for its newest biological fungicide, Stargus, is focused on commercializing its two near-term products: a new herbicide for...

November 14, 2017

Feature

Mazor’s odyssey to spine robotic surgery leader

By Len Zehr Since its founding 15 years ago, Mazor Robotics (NASDAQ, TASE:MZOR) has overcome challenges typical to medical device startups to become the leader and possibly the standard of care in spine robotics surgery...

October 31, 2017

Feature

Flex Pharma focused on 3 clinical readouts in 2018

By Len Zehr Flex Pharma (NASDAQ:FLKS) expects to report clinical readouts in 2018 from three Phase 2 studies of its anti-cramping drug candidate, FLX-787, in amyotrophic lateral sclerosis (ALS), Charcot-Marie-Tooth...

October 24, 2017

Feature

Thera sees ibalizumab as company game changer

By Len Zehr If approved by the FDA in the next few months, ibalizumab for patients with multidrug resistant HIV has the potential to be a game changer for Theratechnologies (TSX:TH). The FDA accepted ibalizumab for...

October 17, 2017

Feature

Titan’s next ProNeura implant could be game changer in PD

By Len Zehr After gaining widespread attention with its FDA-approved Probuphine implant for the maintenance treatment of opioid addiction, Titan Pharmaceuticals (NASDAQ:TTNP) is setting out to develop an implant to...

October 10, 2017

Category - Feature

Subscribe